Start the conversation
In several of our chats, I've said that with this one stock you get both an ETF on the future and a company that produces great profit margins today.
To be sure, the stock lagged the overall market over the past few months. That's largely because industry analysts thought Google's futuristic ambitions would shred profits.
But all that changed on July 16, when Google reported excellent second-quarter results that sent the shares up more than 16%. The move added nearly $70 billion in shareholder value in a single session, a record on Wall Street.
Google made this huge leap largely because it followed one of the rules in "Your Tech Wealth Blueprint."
The question now is: Does Google have any upside left?
Today I've got the answer…
Eye on the Future…
You'd be hard pressed to find a company investing more heavily in turning itself into the high-tech conglomerate of the future.
Google is at the forefront of driverless cars, racking up more than 2 million miles in the last few years. It's also quietly become a leader in robotics by acquiring several companies in the space, including its 2013 purchase of industry pioneer Boston Dynamics.
Google recently joined with Fidelity Investments in a $1 billion investment in Space Exploration Technologies Corp. (that is, Elon Musk's SpaceX). And it has a $1.5 billion partnership with AbbVie Inc. (NYSE: ABBV) in the antiaging concern California Life Sciences (Calico).
But with its impressive second-quarter results, the Silicon Valley leader also proved it's ruthlessly devoted to today's bottom line.
… Focused on the Present
Google turned Wall Street on its ear with a combination of higher sales and stricter cost controls that showed the firm is a profit powerhouse.
Sales rose 11% from the year-ago quarter to $17.7 billion. But earnings per share rose nearly 32%, or nearly three times higher than sales.
These strong results prove that Google meets the mandate of Rule No. 1 of my five-part system for building tech wealth – great companies have great operations.
That almost always means the best tech firms have great leaders. Typically, we look for visionary CEOs to fill that role. But in this case, I believe it's more important to look at Google's new chief financial officer…
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.